DARA Biosciences (NASDAQ: DARA) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare DARA Biosciences to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, dividends and risk.
Insider & Institutional Ownership
65.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
DARA Biosciences has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, DARA Biosciences’ rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.
This table compares DARA Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DARA Biosciences Competitors||-547.39%||-39.23%||-21.46%|
This is a summary of current ratings for DARA Biosciences and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DARA Biosciences Competitors||73||344||1003||29||2.68|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.91%. Given DARA Biosciences’ rivals higher possible upside, analysts clearly believe DARA Biosciences has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares DARA Biosciences and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DARA Biosciences Competitors||$3.02 billion||$642.98 million||-31.09|
DARA Biosciences’ rivals have higher revenue and earnings than DARA Biosciences. DARA Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
DARA Biosciences rivals beat DARA Biosciences on 7 of the 8 factors compared.
About DARA Biosciences
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
What are top analysts saying about DARA Biosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DARA Biosciences Inc and related companies.